ArticlePeerJ2026
Development and prognostic evaluation of a combined SII-LNR score in resectable gastric and gastroesophageal junction adenocarcinoma treated with perioperative FLOT: a retrospective single-center study.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The systemic immune-inflammation index (SII) and lymph node ratio (LNR) have both been associated with survival in gastric and gastroesophageal junction (GEJ) adenocarcinoma, but their combined prognostic value is unclear in patients treated with perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT). We developed a combined SII-LNR risk score and assessed its association with overall survival (OS) and disease-free survival (DFS). Methods: This retrospective single-center cohort included 153 patients with resectable gastric or GEJ adenocarcinoma treated with perioperative FLOT. SII was calculated from pretreatment complete blood counts and LNR from postoperative pathology. OS and DFS were evaluated using Kaplan-Meier methods and Cox proportional hazards regression. Cut-offs were defined using receiver operating characteristic (ROC) analysis with the Youden index, and area under the curve (AUC) values were reported. Results: ROC-derived cut-offs were 715 for SII (AUC 0.602) and 0.13 for LNR (AUC 0.751). The combined SII-LNR score categorized patients into low-risk ( Conclusion: The combined SII-LNR score stratified patients with resectable gastric and GEJ adenocarcinoma treated with perioperative FLOT into distinct postoperative OS and DFS risk groups. If confirmed in multicenter cohorts, it may help identify patients who warrant closer postoperative follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.